دورية أكاديمية
أعرض في EDS

Immunologic mediators profile in COVID-19 convalescence.

التفاصيل البيبلوغرافية
العنوان: Immunologic mediators profile in COVID-19 convalescence.
المؤلفون: Silva-Junior AL; Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Oliveira LS; Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Dias S; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil., Costa TCC; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Xabregas LA; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Alves-Hanna FS; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil., Abrahim CMM; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Neves WLL; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Crispim MAE; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Toro DM; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil., Silva-Neto PV; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil., Aponte DCM; Hospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil., Oliveira TC; Hospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil., Silva MCC; Rede Genômica em Saúde do Estado do Amazonas (REGESAM), Manaus, AM, Brazil., Matos MMM; Hospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil., Carvalho MPSS; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Tarragô AM; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil.; Rede Genômica em Saúde do Estado do Amazonas (REGESAM), Manaus, AM, Brazil., Fraiji NA; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil., Faccioli LH; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil., Sorgi CA; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.; Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil., Sabino EC; Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, SP, Brazil., Teixeira-Carvalho A; Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, MG, Brazil., Martins-Filho OA; Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, MG, Brazil., Costa AG; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil. allyson.gui.costa@gmail.com.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil. allyson.gui.costa@gmail.com.; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil. allyson.gui.costa@gmail.com.; Rede Genômica em Saúde do Estado do Amazonas (REGESAM), Manaus, AM, Brazil. allyson.gui.costa@gmail.com., Malheiro A; Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.; Departamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.; Rede Genômica em Saúde do Estado do Amazonas (REGESAM), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.
المصدر: Scientific reports [Sci Rep] 2024 Sep 09; Vol. 14 (1), pp. 20930. Date of Electronic Publication: 2024 Sep 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: COVID-19*/immunology , COVID-19*/blood , Convalescence* , SARS-CoV-2*/immunology , Immunoglobulin G*/blood , Immunoglobulin G*/immunology , Antibodies, Viral*/blood , Antibodies, Viral*/immunology , Cytokines*/blood, Humans ; Male ; Female ; Adult ; Middle Aged ; Immunoglobulin M/blood ; Immunoglobulin M/immunology ; Longitudinal Studies ; Aged ; Eosinophils/immunology ; Eosinophils/metabolism
مستخلص: SARS-CoV-2 caused the pandemic situation experienced since the beginning of 2020, and many countries faced the rapid spread and severe form of the disease. Mechanisms of interaction between the virus and the host were observed during acute phase, but few data are available when related to immunity dynamics in convalescents. We conducted a longitudinal study, with 51 healthy donors and 62 COVID-19 convalescent patients, which these had a 2-month follow-up after symptoms recovery. Venous blood sample was obtained from all participants to measure blood count, subpopulations of monocytes, lymphocytes, natural killer cells and dendritic cells. Serum was used to measure cytokines, chemokines, growth factors, anti-N IgG and anti-S IgG/IgM antibodies. Statistic was performed by Kruskal-Wallis test, and linear regression with days post symptoms and antibody titers. All analysis had confidence interval of 95%. Less than 35% of convalescents were anti-S IgM+, while more than 80% were IgG+ in D30. Anti-N IgG decreased along time, with loss of seroreactivity of 13%. Eosinophil count played a distinct role on both antibodies during all study, and the convalescence was orchestrated by higher neutrophil-to-lymphocyte ratio and IL-15, but initial stages were marked by increase in myeloid DCs, B1 lymphocytes, inflammatory and patrolling monocytes, G-CSF and IL-2. Later convalescence seemed to change to cytotoxicity mediated by T lymphocytes, plasmacytoid DCs, VEGF, IL-9 and CXCL10. Anti-S IgG antibodies showed the longest perseverance and may be a better option for diagnosis. The inflammatory pattern is yet present on initial stage of convalescence, but quickly shifts to a reparative dynamic. Meanwhile eosinophils seem to play a role on anti-N levels in convalescence, although may not be the major causative agent. We must highlight the importance of immunological markers on acute clinical outcomes, but their comprehension to potentialize adaptive system must be explored to improve immunizations and further preventive policies.
(© 2024. The Author(s).)
References: Sci Transl Med. 2021 Jun 2;13(596):. (PMID: 33979301)
Cell Mol Immunol. 2020 Jun;17(6):672-674. (PMID: 32382127)
Cells. 2021 Sep 06;10(9):. (PMID: 34571981)
Nat Rev Microbiol. 2022 May;20(5):270-284. (PMID: 35354968)
Lancet Infect Dis. 2021 Jun;21(6):803-812. (PMID: 33548194)
Front Cell Dev Biol. 2021 Feb 25;9:620730. (PMID: 33718360)
Mayo Clin Proc. 2021 Feb;96(2):500-502. (PMID: 33549269)
Hum Immunol. 2021 Mar;82(3):170-176. (PMID: 33531264)
Immunity. 2020 Oct 13;53(4):864-877.e5. (PMID: 32791036)
Blood. 2020 Sep 3;136(10):1169-1179. (PMID: 32597954)
J Infect Dis. 2020 Nov 13;222(12):1985-1996. (PMID: 32941618)
Int J Infect Dis. 2022 Nov;124:55-64. (PMID: 36116671)
Front Immunol. 2021 Jun 16;12:708523. (PMID: 34220870)
Cell Rep Med. 2020 Aug 25;1(5):100078. (PMID: 32838342)
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4. (PMID: 32360286)
J Leukoc Biol. 2021 Jan;109(1):13-22. (PMID: 33040384)
Nat Immunol. 2021 Mar;22(3):322-335. (PMID: 33531712)
Nat Commun. 2021 Jun 30;12(1):4043. (PMID: 34193870)
Infect Drug Resist. 2020 Aug 12;13:2819-2828. (PMID: 32848431)
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100763. (PMID: 33997476)
Trends Immunol. 2020 Dec;41(12):1100-1115. (PMID: 33132005)
J Community Hosp Intern Med Perspect. 2020 Oct 29;10(6):514-520. (PMID: 33194120)
Cell Mol Immunol. 2021 Apr;18(4):936-944. (PMID: 33139905)
Sci Immunol. 2022 Jul 22;7(73):eabl9464. (PMID: 35857584)
J Thromb Thrombolysis. 2021 Feb;51(2):446-453. (PMID: 33151461)
J Allergy Clin Immunol. 2021 Oct;148(4):996-1006.e18. (PMID: 34339730)
Exp Eye Res. 2020 Nov;200:108253. (PMID: 32949577)
Environ Chem Lett. 2021;19(4):2773-2787. (PMID: 33846683)
Front Immunol. 2021 May 26;12:647824. (PMID: 34122407)
PLoS One. 2021 Jun 28;16(6):e0252599. (PMID: 34181675)
Platelets. 2021 Nov 17;32(8):1092-1102. (PMID: 33999778)
Nature. 2021 Mar;591(7851):639-644. (PMID: 33461210)
BMJ. 2020 Oct 23;371:m3862. (PMID: 33097561)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
Cell Mol Immunol. 2020 May;17(5):533-535. (PMID: 32203188)
EBioMedicine. 2021 Jul;69:103458. (PMID: 34186492)
Vaccines (Basel). 2022 Aug 31;10(9):. (PMID: 36146515)
Nat Rev Microbiol. 2019 Mar;17(3):181-192. (PMID: 30531947)
Cell. 2021 Mar 4;184(5):1201-1213.e14. (PMID: 33571429)
Cell Rep. 2021 Oct 5;37(1):109798. (PMID: 34587481)
Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):. (PMID: 34548411)
Clin Chem Lab Med. 2020 Dec 09;59(4):783-793. (PMID: 33554540)
PLoS Pathog. 2023 Jun 13;19(6):e1011432. (PMID: 37311004)
Ann Med Surg (Lond). 2021 Feb;62:68-72. (PMID: 33437468)
Sci Rep. 2021 Oct 12;11(1):20254. (PMID: 34642411)
Nat Commun. 2021 Feb 17;12(1):1084. (PMID: 33597531)
Signal Transduct Target Ther. 2020 Aug 14;5(1):156. (PMID: 32796814)
PLoS One. 2022 Apr 21;17(4):e0267102. (PMID: 35446889)
PLoS Pathog. 2021 Oct 6;17(10):e1009742. (PMID: 34614036)
Nat Mater. 2021 May;20(5):593-605. (PMID: 33589798)
EBioMedicine. 2020 Aug;58:102925. (PMID: 32745993)
Korean J Intern Med. 2022 Jan;37(1):201-209. (PMID: 34565131)
Scott Med J. 2020 Nov;65(4):154-160. (PMID: 32865157)
Science. 2020 Sep 4;369(6508):1210-1220. (PMID: 32788292)
Cell Discov. 2021 Apr 13;7(1):24. (PMID: 33850112)
Cell Metab. 2021 Feb 2;33(2):258-269.e3. (PMID: 33421384)
J Clin Apher. 2020 Aug;35(4):367-373. (PMID: 32643200)
Cell. 2020 Apr 16;181(2):223-227. (PMID: 32220310)
Wellcome Open Res. 2021 Feb 22;6:38. (PMID: 33997298)
Sci Immunol. 2021 Aug 10;6(62):. (PMID: 34376481)
Cells. 2020 Sep 29;9(10):. (PMID: 33003471)
Front Immunol. 2020 Dec 03;11:611004. (PMID: 33343585)
J Med Virol. 2021 Mar;93(3):1589-1598. (PMID: 32910458)
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):988-994. (PMID: 33267662)
Elife. 2022 Sep 22;11:. (PMID: 36135358)
Cell Discov. 2020 Oct 20;6:73. (PMID: 33101705)
Cell Mol Immunol. 2021 Mar;18(3):604-612. (PMID: 33060840)
Nat Immunol. 2020 Sep;21(9):1107-1118. (PMID: 32788748)
معلومات مُعتمدة: PCTI-EMERGESAÚDE/AM-Chamada II Program #006/2020 Fundação de Amparo à Pesquisa do Estado do Amazonas; POSGRAD Program #002/2023 Fundação de Amparo à Pesquisa do Estado do Amazonas; POSGRAD Program #002/2024 Fundação de Amparo à Pesquisa do Estado do Amazonas; Pró-Estado Program #002/2008 Fundação de Amparo à Pesquisa do Estado do Amazonas; Pró-Estado Program #007/2018 Fundação de Amparo à Pesquisa do Estado do Amazonas; Pró-Estado Program #005/2019 Fundação de Amparo à Pesquisa do Estado do Amazonas; PQ fellowships Conselho Nacional de Desenvolvimento Científico e Tecnológico; PROCAD-Amazônia 2018 Program - #88881.200581/2018-01 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
فهرسة مساهمة: Keywords: Antibody; Brazil; Immune hallmarks; Severe acute respiratory syndrome (SARS)
المشرفين على المادة: 0 (Immunoglobulin G)
0 (Antibodies, Viral)
0 (Cytokines)
0 (Immunoglobulin M)
تواريخ الأحداث: Date Created: 20240909 Date Completed: 20240909 Latest Revision: 20240912
رمز التحديث: 20240912
مُعرف محوري في PubMed: PMC11384766
DOI: 10.1038/s41598-024-71419-x
PMID: 39251702
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-71419-x